Previously (in early August), we mentioned that there was a miss, in certain head and neck cancers.

Overall, though — it remains a viable combo, in certain kidney and uterine cancers.

Here’s the latest, in any event — from Reuters:

…[Both companies said on] Friday a combination of their cancer therapies did not prolong the lives of patients in two late-stage studies testing it as a treatment for a type of lung cancer.

The pairing of Merck’s blockbuster immunotherapy Keytruda and Eisai’s Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well….

Now you know, but Keytruda is — and will remain — the most profitable drug in Merck’s storied 100 plus year history. And to be clear — Merck is, and will remain — for decades to come… one of the most profitable multinationals on the planet.

So it is a little rich, that Merck refuses to discuss pricing with large customers on very mature, very overpriced diabetes medications like… Januvia. Ugh. But you’ve heard that tune, from me — a few times before. Onward, and… go Buffs… beat the Ducks!

नमस्ते